<DOC>
	<DOC>NCT00437437</DOC>
	<brief_summary>The purpose of this trial is to determine the effect of food versus a fasted state on single-dose pharmacokinetics of BMS-540215, the active metabolite of Brivanib alaninate</brief_summary>
	<brief_title>A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)</brief_title>
	<detailed_description />
	<criteria>For additional information, please contact the BMS oncology clinical trial information service at 8552160126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation. Histologic/cytologic diagnosis of advanced or metastatic solid tumors ECOG 02 4/6 weeks since prior therapy Brain metastases Second primary malignancy Thromboembolic disease requiring full anticoagulation within 6 months Inability to swallow or absorb oral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Advanced or metastatic solid tumors</keyword>
</DOC>